On the other hand, increased percentages of GM-CSF-expressing leukocytes have been found in blood of COVID-19 patients and no clinical benefits of recombinant hGM-CSF treatment have yet been reported for treating COVID-19 patients (43), whereas mAb-induced neutralization of hGM-CSF protein has attracted great interest as an anti-inflammatory therapy for COVID-19 patients (43). The gene discussed is CSF2; the disease is COVID-19.